Arcellx, Inc. (ACLX)

52.69 -0.60 (-1.13%) At close: 04:00PM EDT

Arcellx, Inc.

800 Bridge Parkway
Redwood City, CA 94065
United States
240 327 0603
https://www.arcellx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 130

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Rami Elghandour	Chairman of the Board, CEO & President	941.67k	N/A	1979
Ms. Michelle Lim Gilson	Chief Financial Officer	602.8k	N/A	1993
Dr. Christopher R. Heery M.D.	Chief Medical Officer	683.4k	N/A	1980
Mr. Narinderjeet Singh M.S.	Chief Technical Officer	N/A	N/A	1972
Mr. David Tice Ph.D.	Chief Scientific Officer	N/A	N/A	1971
Ms. Myesha Lacy	Chief Investor & Communications Officer	N/A	N/A	N/A
Ms. Maryam Abdul-Kareem J.D., M.S.	General Counsel & Chief Legal Officer	N/A	N/A	N/A
Ms. Kate Aiken	Chief People Officer	N/A	N/A	N/A
Mr. Neeraj P. Teotia	Chief Commercial Officer	461.95k	N/A	1975
Ms. Aileen Fernandes	Chief Business Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Corporate governance

Arcellx, Inc.’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.